OMC
MYGN icon

Old Mission Capital’s Myriad Genetics MYGN Stock Holding History

Old Mission Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,463
Closed -$320K – 1174
2021
Q2 		$320K Buy
+10,463
New +$302K 0.01% 755

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Old Mission Capital's MYGN Position: Q3 2021 in Review

Old Mission Capital sold out of Myriad Genetics (MYGN) in Q3 2021, closing a stake of 10,463 shares — an estimated $320K sold.

Old Mission Capital first reported a position in MYGN in Q2 2021 and held it in 1 quarter. The position peaked at $320K in Q2 2021. 213 funds tracked by Wall St. Rank hold MYGN as of Q3 2021.

  • Old Mission Capital reported no remaining Myriad Genetics position as of Q3 2021 after selling out during the quarter.
  • Old Mission Capital sold 10,463 Myriad Genetics shares in Q3 2021, an estimated $320K.
  • Old Mission Capital first reported a position in Myriad Genetics in Q2 2021 and held it in 1 quarter.
  • Old Mission Capital's Myriad Genetics position peaked at $320K in Q2 2021.
  • 213 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2021.

Based on Old Mission Capital's 13F filing for Q3 2021, filed 12 Nov 2021.